Oculis (OCS) H.C. Wainwright 4th Annual Ophthalmology Virtual Conference summary

Conference overview

• H.C. Wainwright hosted its fourth annual ophthalmology conference, featuring presentations from industry leaders and updates on innovative eye care solutions.

• Oculis presented significant clinical and financial milestones, highlighting its focus on advancing ophthalmic therapies.

Key clinical developments

• OCS-01, a topical eye drop for diabetic macular edema, demonstrated efficacy comparable to injections in phase III trials, with rapid and sustained vision improvement and strong safety profile.

• OCS-01 addresses two major patient segments: early intervention and those unresponsive to current treatments, potentially expanding the market to $6 billion.

• OCS-02, a TNF inhibitor for dry eye, offers a precision medicine approach, enabling identification of responders before treatment.

• OCS-05, a neuroprotective agent, showed promise in animal models for protecting retinal ganglion cells and axons, with ongoing phase II trials in acute optic neuritis and plans for U.S. IND submission in fall 2024.

Financial and strategic highlights

• Oculis raised $205 million through public listings in the U.S. and Iceland, ensuring funding through late 2026.

• The company efficiently transitioned from a hospital project to a multi-asset, late-stage biopharma, with a balanced portfolio and multiple near-term catalysts.